Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study - Summary - MDSpire
Advertisement
Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study
To quantify the real-world effectiveness and safety of dupilumab therapy in children aged ≤6 years with asthma that remains uncontrolled despite standard therapies.
Approach:
Key Findings:
Dupilumab therapy was associated with a reduction in acute exacerbations at 6 months (RR 0.53) and 12 months (RR 0.46; p < 0.05).
Reduced oral corticosteroid (OCS) use was observed at 6 months (RR 0.67) and 12 months (RR 0.66; p < 0.05).
Lower rates of emergency room visits and infections were noted (all p < 0.05).
Increased risk of anaphylaxis was reported in the dupilumab cohort at 6 months (RR 1.80) and 12 months (RR 1.74; p < 0.05).
Other outcomes such as status asthmaticus, eosinophilia, and inpatient admissions were similar between cohorts.
Interpretation:
Remove or revise to eliminate unsupported conclusions.
Limitations:
The study is retrospective and may be subject to biases inherent in observational data.
The cohort may not fully represent all demographic groups due to the nature of the data source.
Conclusion:
Revise to avoid unsupported claims about clinical benefit.
